Investigational drug · Phase 2
Diranersen
Also called: ISIS 814907, BIIB080
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Diranersen"
First trial start
2022
Aug 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Diranersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Alzheimer's Disease Dementia
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Diranersen" as an intervention, largest first.
- A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgePivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT05399888 · 416 participants · Start Aug 24, 2022 · Primary completion Mar 11, 2026
Drug: Diranersen; Diranersen-matching placebo · For: Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 138 sites in all
BiogenBiogen (BIIB)
NCT06454721 · 5 participants · Start Jan 30, 2025 · Primary completion Mar 5, 2026
Drug: [89Zr]Zr-DFO-Diranersen; Diranersen · For: Healthy Volunteer
Sites: Sacramento, California
Newest research
PubMed records naming it or its code names, newest first.
- Alternative splicing in Alzheimer's disease: event-level evidence, risk-locus biology, and RNA-based therapeutic perspectives.
Li J, Yue D, Xie W, et al. · Gene 2026
- From target engagement to translational disconnect: A systematic review and narrative synthesis of direct tau-targeted clinical trials in Alzheimer's disease and primary tauopathies.
Yin L, Ren R, Leo C, et al. · Pharmacol Res 2026
- Decoding MAPT Exon 10 Mis-Splicing in FTDP-17: From Pathogenic Mechanisms and Experimental Models to Molecular Therapies.
Covello G · Genes (Basel) 2026
- Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease.
Shulman M, Wu S, Ziogas N, et al. · Nat Aging 2026
- PET imaging of antisense oligonucleotide distribution in rat and nonhuman primate brains using click chemistry.
Cook BE, Pickel TC, Nag S, et al. · Sci Transl Med 2025
- Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
Edwards AL, Collins JA, Junge C, et al. · JAMA Neurol 2023
Also in development for Mild Cognitive Impairment Due to Alzheimer's Disease
- PRI-002ContraloidPhase 21 trial
PRInnovation GmbH · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Biogen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.